General Announcement::Glenmark introduces NINDANIB (Nintedanib) in India

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
14-Oct-2020 12:56:56
Status
New
Announcement Sub Title
Glenmark introduces NINDANIB (Nintedanib) in India
Announcement Reference
SG201014OTHRDLXZ
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals Limited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
14/10/2020 00:00:00
Description (Please provide a detailed description of the event in the box below)
Glenmark introduces NINDANIB (Nintedanib) and is amongst the first to launch the branded generic version at an affordable cost for the treatment of Pulmonary Fibrosis in India

Attachments

SGX_PR_14102020.pdf
Total size =1382K